Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis

Lucio BOGLIONE; Amedeo De Nicolò; Simone Mornese Pinna; Jessica Cusato; Giuseppe Cariti; Giovanni Di Perri; Antonio D'Avolio

doi:10.1159/000491646

Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis

Lucio BOGLIONE, Amedeo De Nicolò, Simone Mornese Pinna, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Backround: The effect of methadone (MET) during therapy with novel direct-acting antiviral agents is still not fully understood. Currently, no data are available about the influence of MET on daclatasvir (DCV) plasma levels in patients affected by chronic hepatitis C (CHC). The aim of this study was to assess the DCV plasma concentrations in patients treated with sofosbuvir (SOF) plus DCV, with or without ribavirin (RBV) and with or without MET.

Lingua originale	Inglese
pagine (da-a)	184-188
Numero di pagine	5
Rivista	European Addiction Research
Volume	24
Numero di pubblicazione	4
DOI	https://doi.org/10.1159/000491646
Stato di pubblicazione	Pubblicato - 2018

Keywords

Cirrhotic
Daclatasvir
Hepatitis C virus
Methadone
Pharmacokinetic
Therapeutic drug monitoring

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1159/000491646

http://hdl.handle.net/11579/113956

Altri file e collegamenti

handle

Cita questo

@article{2a71316f57c94fa39c80325d957f3b16,

title = "Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis",

abstract = "Backround: The effect of methadone (MET) during therapy with novel direct-acting antiviral agents is still not fully understood. Currently, no data are available about the influence of MET on daclatasvir (DCV) plasma levels in patients affected by chronic hepatitis C (CHC). The aim of this study was to assess the DCV plasma concentrations in patients treated with sofosbuvir (SOF) plus DCV, with or without ribavirin (RBV) and with or without MET.",

keywords = "Cirrhotic, Daclatasvir, Hepatitis C virus, Methadone, Pharmacokinetic, Therapeutic drug monitoring, Cirrhotic, Daclatasvir, Hepatitis C virus, Methadone, Pharmacokinetic, Therapeutic drug monitoring",

author = "Lucio BOGLIONE and {De Nicol{\`o}}, Amedeo and {Mornese Pinna}, Simone and Jessica Cusato and Giuseppe Cariti and {Di Perri}, Giovanni and Antonio D'Avolio",

year = "2018",

doi = "10.1159/000491646",

language = "English",

volume = "24",

pages = "184--188",

journal = "European Addiction Research",

issn = "1022-6877",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis

AU - BOGLIONE, Lucio

AU - De Nicolò, Amedeo

AU - Mornese Pinna, Simone

AU - Cusato, Jessica

AU - Cariti, Giuseppe

AU - Di Perri, Giovanni

AU - D'Avolio, Antonio

PY - 2018

Y1 - 2018

N2 - Backround: The effect of methadone (MET) during therapy with novel direct-acting antiviral agents is still not fully understood. Currently, no data are available about the influence of MET on daclatasvir (DCV) plasma levels in patients affected by chronic hepatitis C (CHC). The aim of this study was to assess the DCV plasma concentrations in patients treated with sofosbuvir (SOF) plus DCV, with or without ribavirin (RBV) and with or without MET.

AB - Backround: The effect of methadone (MET) during therapy with novel direct-acting antiviral agents is still not fully understood. Currently, no data are available about the influence of MET on daclatasvir (DCV) plasma levels in patients affected by chronic hepatitis C (CHC). The aim of this study was to assess the DCV plasma concentrations in patients treated with sofosbuvir (SOF) plus DCV, with or without ribavirin (RBV) and with or without MET.

KW - Cirrhotic

KW - Daclatasvir

KW - Hepatitis C virus

KW - Methadone

KW - Pharmacokinetic

KW - Therapeutic drug monitoring

KW - Cirrhotic

KW - Daclatasvir

KW - Hepatitis C virus

KW - Methadone

KW - Pharmacokinetic

KW - Therapeutic drug monitoring

UR - https://iris.uniupo.it/handle/11579/113956

U2 - 10.1159/000491646

DO - 10.1159/000491646

M3 - Article

SN - 1022-6877

VL - 24

SP - 184

EP - 188

JO - European Addiction Research

JF - European Addiction Research

IS - 4

ER -

Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo